FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib. [electronic resource]
Producer: 20090611Description: 845-51 p. digitalISSN:- 1476-5551
- Aged
- Animals
- Benzenesulfonates -- therapeutic use
- Blast Crisis
- Blotting, Western
- Cells, Cultured
- Chronic Disease
- Drug Resistance, Neoplasm
- Humans
- Hypereosinophilic Syndrome -- drug therapy
- Male
- Mice
- Mutation -- genetics
- Niacinamide -- analogs & derivatives
- Oncogene Proteins, Fusion -- genetics
- Phenylurea Compounds
- Phosphorylation -- drug effects
- Precursor Cells, B-Lymphoid -- cytology
- Protein Kinase Inhibitors -- therapeutic use
- Pyridines -- therapeutic use
- Receptor, Platelet-Derived Growth Factor alpha -- genetics
- Receptors, Vascular Endothelial Growth Factor -- antagonists & inhibitors
- Salvage Therapy
- Sorafenib
- mRNA Cleavage and Polyadenylation Factors -- genetics
No physical items for this record
Publication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.